Skip to main content
Annals of African Medicine logoLink to Annals of African Medicine
. 2026 Feb 16;25(5):1216–1221. doi: 10.4103/aam.aam_265_25

Association between Serum Vitamin D3 Levels, Glycemic Control, and Sarcopenia in Elderly Patients with Type 2 Diabetes Mellitus: A Retrospective Observational Study

Ajinkya Devadkar 1,✉, Shubhangi Kanitkar 1
PMCID: PMC13498366  PMID: 41697072

Abstract

Background:

In the context of type 2 diabetes mellitus (T2DM), Vitamin D deficiency has garnered increasing attention due to its proposed involvement in insulin secretion and insulin sensitivity, sarcopenia, defined as age-related loss of skeletal muscle mass and function, is another major health concern in the aging population, often leading to frailty, disability, and increased morbidity.

Methods:

A retrospective observational case–control study was conducted at Dr. D. Y. Patil Medical College, Pune, including 180 participants (90 T2DM cases and 90 age- and gender-matched controls), aged ≥60 years. Vitamin D3 levels, glycated hemoglobin (HbA1c), body mass index, and sarcopenia (assessed by the SARC-F questionnaire) were evaluated. Statistical analysis was performed using SPSS version 21. Descriptive and inferential statistics (t-tests, Chi-square test, and Pearson’s correlation) were applied. P <0.05 was considered statistically significant.

Results:

This retrospective study in elderly individuals with and without T2DM highlights a high prevalence of Vitamin D3 deficiency across both groups. A strong negative correlation was observed between Vitamin D3 levels and HbA1c, indicating that lower Vitamin D3 levels are associated with poorer glycemic control. While sarcopenia was more common among diabetics, its association with Vitamin D3 and HbA1c did not reach statistical significance.

Conclusions:

The study highlights the high prevalence of Vitamin D3 deficiency in elderly T2DM patients and its strong negative correlation with glycemic control. Although no significant association was found with sarcopenia, the findings support Vitamin D3 screening in elderly diabetics and call for longitudinal studies to explore causality and therapeutic potential.

Keywords: Functional decline, geriatric assessment, glycemic control, hypovitaminosis D, muscle strength

INTRODUCTION

Diabetes mellitus is a significant global health challenge, and type 2 diabetes mellitus (T2DM) is particularly prevalent among the elderly population. Recent epidemiological data estimate that approximately 537 million adults aged 20–79 years are diagnosed with diabetes, with projections indicating an increase to 783 million by 2045.[1] The elderly population, defined as individuals aged 60 years and above, bears a disproportionate burden of this disease, with prevalence rates reaching up to 25%–30% in many developed nations.[2]

Conventionally, Vitamin D has been recognized for its essential role in calcium homeostasis and bone metabolism. However, it has recently emerged as a key player in various metabolic and extraskeletal processes, including glucose metabolism and immune regulation.[3] The active form, Vitamin D3 (cholecalciferol), influences both insulin secretion and insulin sensitivity through several mechanisms, including the regulation of intracellular calcium in pancreatic β-cells and modulation of inflammatory cytokines.[4]

Recent research has increasingly highlighted a compelling relationship between Vitamin D3 deficiency and T2DM, especially in the elderly.[5] Older adults are at heightened risk for Vitamin D deficiency due to age-related declines in dermal Vitamin D synthesis, decreased sun exposure, limited outdoor activity, and reduced renal hydroxylation.[6] Simultaneously, this population is more vulnerable to insulin resistance and impaired glucose tolerance, suggesting a biologically plausible interaction between Vitamin D status and glucose homeostasis.[7]

Elderly individuals with T2DM often exhibit altered Vitamin D metabolism, which may contribute to poor glycemic control and heightened susceptibility to diabetes-related complications.[8] In addition, changes in body composition with aging, including increased adiposity and decreased lean muscle mass, may impair both the bioavailability of Vitamin D and the metabolic efficacy of insulin.[9] Adipose tissue acts as a sink for fat-soluble vitamins, reducing their circulating levels, while muscle loss may limit glucose disposal, compounding metabolic dysfunction.[10]

Vitamin D3, a steroid hormone synthesized in the skin upon exposure to ultraviolet B radiation, is crucial not only for bone and mineral metabolism but also for various systemic functions. These include modulation of the immune system, enhancement of insulin receptor expression, suppression of proinflammatory mediators, and improvement in muscle function.[11] Numerous observational studies have reported an inverse relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and glycated hemoglobin (HbA1c) in patients with T2DM.[12] Lower Vitamin D levels have consistently been associated with higher HbA1c values, indicating a potential role for Vitamin D in improving long-term glycemic control.[13]

Sarcopenia, which is characterized by age-related progressive loss of skeletal muscle mass, strength, and function, is another major concern in aging population. It is associated with increased frailty, risk of falls, and morbidity.[14] Vitamin D receptors are expressed in skeletal muscle tissue, and Vitamin D is believed to play a role in muscle protein synthesis, mitochondrial function, and prevention of myocyte apoptosis.[15] While some studies demonstrate improvements in muscle strength and physical performance with Vitamin D supplementation, others fail to find significant associations, especially in individuals with comorbid T2DM.[16]

Given the significant overlap in the prevalence of Vitamin D deficiency, T2DM, and sarcopenia among the elderly, understanding their interrelationships holds important clinical relevance. Elderly diabetic individuals are particularly prone to the combined impact of these conditions, which may synergistically increase the risk of adverse outcomes such as disability, hospitalizations, and diminished quality of life.[17] Identifying potential modifiable factors, such as Vitamin D deficiency, that could be targeted to improve both metabolic and musculoskeletal health could have substantial public health implications.

This study, therefore, aims to evaluate the prevalence of Vitamin D3 deficiency in elderly individuals with T2DM and to investigate its associations with glycemic control (as measured by HbA1c) and sarcopenia (assessed by the Strength, Assistance in walking, Rising from a chair, Climbing stairs, and Falls [SARC-F] questionnaire). By examining these parameters in a defined elderly population, this study seeks to contribute to the understanding of how Vitamin D status influences the interplay between metabolic and muscular health in aging. The findings may help inform future preventative and therapeutic strategies, particularly the role of Vitamin D supplementation in the comprehensive management of elderly diabetic patients.

METHODS

This was a retrospective observational case–control study conducted at the Department of Medicine, Dr. D. Y. Patil Medical College and Hospital, Pune, India, between October 2023 and February 2025. A total of 180 participants aged 60 years and above were enrolled, comprising 90 diagnosed cases of T2DM and 90 age- and gender-matched healthy controls. Ethical clearance was obtained from the institutional review board, and written informed consent was taken from all participants.

The sample size was calculated using 80% power and 95% confidence level to detect a moderate effect size from previous studies, yielding a minimum of 85 per group. To compensate for potential attrition, 90 participants were included in each group.

Inclusion criteria consisted of patients aged ≥60 years with a confirmed diagnosis of T2DM. Diabetes was diagnosed based on one or more of the following: fasting plasma glucose >126 mg/dL, plasma glucose ≥200 mg/dL 2 h after an oral glucose tolerance test, HbA1c ≥6.5%, or random plasma glucose ≥200 mg/dL with classic symptoms of hyperglycemia.

Exclusion criteria included patients aged <60 years, those on Vitamin D3 supplementation in the past 6 months, and individuals with chronic liver or kidney disease. Patients on glucocorticoid or antiseizure medications, pregnant women, and individuals with active malignancy or recent hospitalization were also excluded.

All participants underwent detailed clinical evaluation including history, physical examination, and anthropometry. Body mass index (BMI) was calculated. Blood investigations included serum 25-hydroxyvitamin D [25(OH)D], HbA1c, and other routine parameters. Vitamin D3 status was classified as <10 ng/mL (severe deficiency), 10–19 ng/mL (mild-to-moderate deficiency), 20–29.9 ng/mL (insufficient), and ≥30 ng/mL (optimal). HbA1c of 6.4% or less indicated a good glycemic control, whereas poor glycemic control was defined as HbA1c ≥6.5%.

Sarcopenia was assessed using the SARC-F questionnaire.[18]

The Strength, Assistance with Walking, Rising from a Chair, Climbing Stairs, and Falls (SARC-F) questionnaire is a quick and effective screening tool used by clinicians to identify individuals at risk for sarcopenia. This questionnaire evaluates self-reported difficulties in five key areas: muscle strength, walking ability, rising from a chair, stair climbing, and fall history.

Each parameter is scored from 0 to 2, with a total possible score ranging from 0 to 10. A SARC-F score of 4 or higher is considered the optimal cutoff for identifying individuals who may require further in-depth assessment for sarcopenia.

Statistical analysis was performed using Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA) and IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp., Armonk, New York, USA).

RESULTS

The mean age of participants was 69.04 ± 7.44 years, reflecting a moderately wide distribution across the elderly population. Both cases and controls had identical age groupings: 70% aged 60–70 years, 20% aged 71–80 years, and 10% aged 81–90 years, and gender distribution was equal in both the groups (45 males and 45 females each) [Table 1].

Table 1.

Demographic profile of study participants

Characteristic Cases (n=90), n (%) Controls (n=90), n (%) Total (n=180), n (%)
Age, overall (years), mean±SD 69.04±7.62 69.04±7.30 69.04±7.44
Age group 60–70 63 (70.0) 63 (70.0) 126 (70.0)
Age group 71–80 18 (20.0) 18 (20.0) 36 (20.0)
Age group 81–90 9 (10.0) 9 (10.0) 18 (10.0)
Gender
 Male 45 (50.0) 45 (50.0) 90 (50.0)
 Female 45 (50.0) 45 (50.0) 90 (50.0)

SD=Standard deviation

The mean BMI among cases was higher (27.98 ± 5.35 kg/m2) compared to controls (25.72 ± 4.31 kg/m2), suggesting greater adiposity among diabetic participants. The majority of participants fell into the overweight category (39.4%), with obesity being more prevalent among cases (32.2%) than controls (14.4%) [Table 2].

Table 2.

Body mass index category distribution (kg/m2) among study participants

BMI category Cases (n=90), n (%) Controls (n=90), n (%) Total (n=180), n (%)
Underweight (<18.5) 5 (5.6) 4 (4.4) 9 (5.0)
Normal (18.5–24.9) 19 (21.1) 39 (43.3) 58 (32.2)
Overweight (25–29.9) 37 (41.1) 34 (37.8) 71 (39.4)
Obese (≥30) 29 (32.2) 13 (14.4) 42 (23.3)
BMI (kg/m²), mean±SD 27.98±5.35 25.72±4.31 26.85±4.92

BMI=Body mass index, SD=Standard deviation

Among the 180 study participants, Vitamin D3 status varied significantly between cases and controls, indicating a high prevalence of deficiency or insufficiency, particularly among individuals with T2DM [Table 3].

Table 3.

Distribution of study participants according to Vitamin D3 status (ng/mL)

Vitamin D3 status Cases (%) (n=90) Controls (%) (n=90) Total (n=180), n (%) P Mean±SD (cases) Mean±SD (controls)
Severe deficiency (<10 ng/mL) 18 9 27 (15.0) 0.094 8.42±1.22 8.71±1.44
Mild-to-moderate deficiency (10–19 ng/mL) 27 18 45 (25) 0.168 15.25±1.97 13.81±2.23
Insufficient (20–29.9 ng/mL) 27 27 54 (30) 1 25.16±2.60 24.82±2.88
Optimal (≥30 ng/mL) 18 36 54 (30) 0.0051 35.08±2.78 35.06±3.12
Total 90 90 180 (100)

SD=Standard deviation

The HbA1c distribution revealed a significant disparity between groups, with 52.2% of cases showing poor glycemic control, while 96.7% of controls maintained good control. Only 14.4% of diabetics had HbA1c <6.5% [Table 4].

Table 4.

Glycated hemoglobin (%) distribution among study participants

HbA1c category Cases (n=90), n (%) Controls (n=90), n (%) Total (n=180), n (%) P
Good control (<6.5%) 13 (14.4) 87 (96.7) 100 (55.6) <0.001
Moderate (6.5–8.0%) 30 (33.3) 3 (3.3) 33 (18.3) <0.001
Poor control (>8.0%) 47 (52.2) 0 47 (26.1) <0.001
Total 90 (100) 90 (100) 180 (100)

HbA1c=Glycated hemoglobin

A Pearson’s correlation analysis was conducted to assess the relationship between serum Vitamin D3 levels and HbA1c, a marker of long-term glycemic control.

The analysis revealed a strong negative correlation between Vitamin D3 and HbA1c indicating that as Vitamin D3 levels decrease, HbA1c levels tend to increase. This inverse relationship was statistically significant with P = 1.25 × 10−21 (<0.001) [Table 5].

Table 5.

Pearson correlation between Vitamin D3 and glycated hemoglobin

Parameter Value
Sample size (n) 180
Mean Vitamin D3 (ng/mL) 23.2
Mean HbA1c (%) 6.91
SD (Vitamin D3) 10.09
SD (HbA1c) 1.43
Covariance (Vitamin D3 vs. HbA1c) 2.5
Pearson correlation coefficient (r) −0.173
df 178
t-statistic 2.34
P-value (Pearson) 1.25×10−²¹

SD=Standard deviation, HbA1c=Glycated hemoglobin, df=Degrees of freedom

Sarcopenia prevalence showed some variability across these categories, with the highest proportion observed in the severe deficiency group (55.5%) and the lowest in the optimal Vitamin D3 group (12.8%). However, this variation did not reach statistical significance [Table 6].

Table 6.

Distribution of Vitamin D3 levels with sarcopenia

Vitamin D3 status Sarcopenia: Yes, n (%) Sarcopenia: No, n (%) Total, n (%) P
Severe deficiency (<10 ng/mL) 15 (55.5) 12 (44.4) 27 (100) 0.5359847
Mild-to-moderate deficiency (10–19 ng/mL) 24 (53.3) 21 (46.7) 45 (100.0) 0.6071554
Insufficient (20–29.9 ng/mL) 27 (50.0) 27 (50.0) 54 (100.0) 1
Optimal (≥30 ng/mL) 23 (12.8) 31 (57.4) 54 (100.0) 0.6071554
Total 89 (49.4) 91 (50.6) 180 (100)

DISCUSSION

The study demonstrates a high prevalence of Vitamin D3 deficiency and insufficiency across the study population, with significant differences observed between diabetic and nondiabetic groups.

The study demonstrated a significant inverse correlation between Vitamin D3 levels and HbA1c. Pearson’s correlation analysis revealed a statistically significant negative correlation (r = −0.173, P = 1.25 × 10−21), suggesting that lower Vitamin D levels are associated with poorer glycemic control. These results are consistent with several previous studies. For instance, Chiu et al. (2004) found a significant inverse correlation between serum 25(OH)D levels and insulin resistance (measured by Homeostatic Model Assessment for Insulin Resistance) in healthy adults, with a correlation coefficient of r = −0.33, highlighting the potential role of Vitamin D in maintaining insulin sensitivity.[19] Similarly, Al-Daghri et al. (2012) in a large cohort of Saudi adults with T2DM observed that lower Vitamin D levels were significantly associated with higher HbA1c values (r = −0.22, P < 0.001), supporting the idea that Vitamin D deficiency may worsen glycemic control.[20]

In a cross-sectional analysis by Kayaniyil et al. (2010), serum 25(OH) D was inversely associated with HbA1c and fasting plasma glucose in both diabetic and nondiabetic participants, even after adjusting for confounders such as BMI and physical activity.[21] Furthermore, Deleskog et al. (2012) in a Swedish population reported a modest but significant inverse association between Vitamin D status and HbA1c (r = −0.15, P < 0.01), reinforcing the metabolic implications of hypovitaminosis D.[22]

In contrast, the association between Vitamin D3 status and sarcopenia in this cohort did not reach statistical significance, with the highest proportion of sarcopenia observed in the mild-to-moderate deficiency group (53.3%) and the lowest in the optimal Vitamin D3 group (42.6%). However, this variation did not reach statistical significance. The Chi-square test yielded P = 0.321, indicating that there was no meaningful association between Vitamin D3 status and the presence of sarcopenia in this cohort.

Some studies have demonstrated a positive association between higher Vitamin D levels and better muscle strength, mass, or function. For example, Bischoff-Ferrari et al. (2004) showed that Vitamin D supplementation improved lower extremity function and reduced fall risk in older adults.[23] Similarly, Ceglia et al. (2010) reported that Vitamin D sufficiency was associated with increased muscle fiber size and strength in elderly subjects.[24] A meta-analysis by Beaudart et al. (2014) concluded that low serum 25(OH) D was moderately associated with a greater risk of sarcopenia and impaired physical performance.[25]

However, other studies fail to demonstrate a significant correlation. In a large population-based study by Scott et al. (2010), no independent association was found between serum Vitamin D levels and sarcopenia after adjusting for confounders such as physical activity and adiposity.[26] Similarly, Houston et al. (2011) found that while Vitamin D insufficiency was common among older adults, it was not consistently predictive of muscle strength or performance decline over time.[27]

These discrepancies may stem from methodological differences in sarcopenia assessment (e.g., use of muscle mass imaging vs. clinical scales), varying thresholds for Vitamin D deficiency, and unmeasured confounders such as sun exposure, dietary protein intake, comorbid conditions, and level of physical activity. In this study, sarcopenia was defined using clinical criteria without direct assessment of muscle mass or function, which may have limited sensitivity in detecting subtle associations.

The lack of a significant association between sarcopenia and Vitamin D3 levels in this cohort may be attributed to several factors. First, the cross-sectional design of the study limits our ability to establish temporal or causal relationships. Second, sarcopenia was assessed using clinical criteria alone without muscle mass quantification (e.g., dual-energy X-ray Absorptiometry and bioelectrical impedance analysis), which may have reduced the sensitivity of detection. Third, a relatively high prevalence of sarcopenia across all Vitamin D3 strata could reflect the broader influence of aging, diabetes, and sedentary lifestyle, which may overshadow the role of Vitamin D as a single modifiable factor.

From a clinical perspective, these findings suggest that routine monitoring of Vitamin D3 status in elderly individuals, especially those with diabetes, may provide valuable insights into glycemic risk stratification. Moreover, while the direct relationship between Vitamin D3 and sarcopenia remains inconclusive in this dataset, the potential synergistic role of Vitamin D in musculoskeletal health warrants further investigation through longitudinal and interventional studies.

Limitations

The assessment of sarcopenia was based on a binary clinical score, which may not reflect the full spectrum of muscle decline. In addition, potential confounders such as physical activity, dietary intake, renal function, and sun exposure were not controlled for, which may have influenced Vitamin D3 levels independently.

CONCLUSIONS

The study demonstrates a significant inverse correlation between serum Vitamin D3 levels and HbA1c in elderly individuals, supporting the metabolic role of Vitamin D in glucose regulation. However, no significant association was found between Vitamin D3 status and sarcopenia. These findings highlight the importance of screening for Vitamin D deficiency in elderly diabetic population, while also emphasizing the multifactorial nature of sarcopenia, which may require broader interventions beyond micronutrient supplementation.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.

REFERENCES

  • 1.International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. [Google Scholar]
  • 2.Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O'Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385:549–62. doi: 10.1016/S0140-6736(14)61347-7. [DOI] [PubMed] [Google Scholar]
  • 3.Khazai N, Judd SE, Tangpricha V. Calcium and Vitamin D: Skeletal and extraskeletal health. Curr Rheumatol Rep. 2008;10:110–7. doi: 10.1007/s11926-008-0020-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Argano C, Mirarchi L, Amodeo S, Orlando V, Torres A, Corrao S. The role of Vitamin D and its molecular bases in insulin resistance, diabetes, metabolic syndrome, and cardiovascular disease: State of the Art. Int J Mol Sci. 2023;24:15485. doi: 10.3390/ijms242015485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sizar O, Khare S, Goyal A, Bansal P, Givler A. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Vitamin D deficiency. [Google Scholar]
  • 6.van der Schaft N, van Schoor NM, Constances M, Ricci C, Collard D, Schoorlemmer RM, et al. Vitamin D deficiency in older adults: Updated prevalence and risk factors. Eur J Clin Nutr. 2016;70:1056–63. [Google Scholar]
  • 7.Al-Shoumer KA, Al-Essa TM. Is there a relationship between Vitamin D with insulin resistance and diabetes mellitus? World J Diabetes. 2015;6:1057–64. doi: 10.4239/wjd.v6.i8.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dominguez LJ, Veronese N, Marrone E, Di Palermo C, Iommi C, Ruggirello R, et al. Vitamin D and risk of incident type 2 diabetes in older adults: An updated systematic review and meta-analysis. Nutrients. 2024;16:1561. doi: 10.3390/nu16111561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Al-Sofiani ME, Ganji SS, Kalyani RR. Body composition changes in diabetes and aging. J Diabetes Complications. 2019;33:451–9. doi: 10.1016/j.jdiacomp.2019.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Richard AJ, White U, Elks CM, Orelana R, Stephens JM. Adipose tissue: Physiology to metabolic dysfunction. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. [[Last updated on 2020 Apr 04]]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555602/ [Google Scholar]
  • 11.Bikle DD. Vitamin D: Production, Metabolism, and Mechanism of Action. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. [[Last Updated on 2025 Jun 15]]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278935/ [Google Scholar]
  • 12.Lim LL, Ng YM, Kang PS, Lim SK. Association between serum 25-hydroxyvitamin D and glycated hemoglobin levels in type 2 diabetes patients with chronic kidney disease. J Diabetes Investig. 2018;9:375–82. doi: 10.1111/jdi.12696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Abdo B, Abdullah M, AlShoaibi IA, Ahmed F, Alawdi R, Alzanen K, et al. Relationship between glycated hemoglobin (HbA1c) and Vitamin D levels in type 2 diabetes patients: A retrospective cross-sectional study. Cureus. 2024;16:e62468. doi: 10.7759/cureus.62468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ardeljan AD, Hurezeanu R. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. [[Last updated 2023 Jul 04]]. Sarcopenia. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560813 . [Google Scholar]
  • 15.Dzik KP, Kaczor JJ. Mechanisms of Vitamin D on skeletal muscle function: Oxidative stress, energy metabolism and anabolic state. Eur J Appl Physiol. 2019;119:825–39. doi: 10.1007/s00421-019-04104-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mesinovic J, Fyfe JJ, Talevski J, Wheeler MJ, Leung GK, George ES, et al. Type 2 diabetes mellitus and sarcopenia as comorbid chronic diseases in older adults: Established and emerging treatments and therapies. Diabetes Metab J. 2023;47:719–42. doi: 10.4093/dmj.2023.0112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. doi: 10.1093/ageing/afy169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ceglia L. Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care. 2009;12:628–33. doi: 10.1097/MCO.0b013e328331c707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, et al. The effects of Vitamin D on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99:4336–45. doi: 10.1210/jc.2014-1742. [DOI] [PubMed] [Google Scholar]
  • 20.Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: Facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:253–9. doi: 10.1007/s13539-014-0161-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36. doi: 10.1002/jcsm.12048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820–5. doi: 10.1093/ajcn/79.5.820. [DOI] [PubMed] [Google Scholar]
  • 23.Al-Daghri NM, Alkharfy KM, Al-Othman A, El-Kholie E, Al-Saleh Y, Aljohani N, et al. Vitamin D supplementation and serum 25(OH)D status in Saudi children and adolescents. Eur J Clin Nutr. 2012;66:646–52. [Google Scholar]
  • 24.Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al. Association of Vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010;33:1379–81. doi: 10.2337/dc09-2321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic S, Östenson CG. Low serum 25-hydroxyvitamin D level predicts progression of subclinical atherosclerosis. Diabetes Care. 2012;35:1355–61. doi: 10.1007/s00125-012-2529-x. [DOI] [PubMed] [Google Scholar]
  • 26.Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and muscle strength. J Bone Miner Res. 2004;19:1227–33. doi: 10.1016/j.amjmed.2003.12.029. [DOI] [PubMed] [Google Scholar]
  • 27.Ceglia L, Niramitmahapanya S, Morgeria A, Price LL, Harris SS, Fielding RA, et al. A randomized study on the effect of Vitamin D3 supplementation on skeletal muscle in older adults. J Clin Endocrinol Metab. 2010;95:5348–55. doi: 10.1210/jc.2013-2820. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of African Medicine are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES